Stockreport

Enanta Pharmaceuticals Announces Positive Topline Results for EDP-323 in a Phase 2a Human Challenge Study of Healthy Adults Infected With Respiratory Syncytial Virus (RSV)

Enanta Pharmaceuticals, Inc.  (ENTA) 
Last enanta pharmaceuticals, inc. earnings: 2/6 04:00 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.enanta.com/investor-overview
PDF Treatment With Once-Daily EDP-323 Met Primary and Secondary Endpoints, Achieving Highly Statistically Significant Reductions in Both Viral Load and Clinical Symptoms Com [Read more]